Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S127-9.

Treatment of palmoplantar psoriasis with intramuscular alefacept.

Author information

  • 1Clinical Research Center, University of Medicine and Dentistry New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901-0019, USA.

Abstract

Alefacept is a dimeric fusion protein that consists of the extracellular CD2-binding portion of human lymphocyte function-associated antigen-3, which is linked to the Fc segment of human IgG1. Alefacept inhibits T-cell activation and proliferation, and induces apoptosis of memory-effector (CD45RO+) T cells in vitro, limiting the inflammatory and uncontrolled keratinocyte proliferation seen in psoriatic lesions. Alefacept is the first biologic approved in the United States for the treatment of moderate to severe chronic plaque psoriasis. This report describes the use of alefacept in 2 patients with extensive and recalcitrant palmoplantar psoriasis who achieved significant improvements on alefacept therapy.

PMID:
16021161
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk